Live Breaking News & Updates on Subcutaneous Route

Stay updated with breaking news from Subcutaneous route. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda today announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application resubmission for the investigational subcutaneous administration of. | April 27, 2023 ....

United States , Abhyankarbj Crohns , Vijay Yajnik , Le Berre , John Cunningham , Exchange Commission , European Union , Drug Administration , Takeda Pharmaceutical Company Limited , Biologics License Application , Response Letter , Ulcerative Colitis , Rare Genetics , Plasma Derived Therapies , Annual Report , Product Characteristics , Vedolizumab Patient Exposure , Pharmacol Exp , Rev Dis , Takeda Pharmaceutical Company Limited Stock Exchange , Press Release , Dministration 4502 Jp3463000004 ,

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained. | April 25, 2023 ....

Omeros Corporation , Omeros Corporation Nasdaq , Mean Hemoglobin Change , Baseline Over Time , Business Wire , About Omeros , Omeros Corporation Stock Exchange , Press Release , Nd Omer Us6821431029 ,

KORU Medical Systems to Report First Quarter Financial Results on May 4, 2023

KORU Medical Systems , a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that. | April 21, 2023 ....

Koru Medical Systems , Nc Stock Exchange , Press Release , Ystems Krmd Us7599101026 ,

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA. | April 20, 2023 ....

United Kingdom , Paul Bolno , Chandra Vargeese , Kate Rausch , Wave Life Sciences Nasdaq , Wave Life Sciences Fourth Quarter , Exchange Commission , Nucleic Acids Research , Wave Life Sciences , Wave Life Sciences Ltd , Life Sciences , Nucleic Acids , Chief Technology Officer , Platform Discovery Sciences , Wave Life , Chief Executive Officer , Life Sciences Fourth Quarter , Full Year , Private Securities Litigation Reform Act , Annual Report , Wave Life Sciences Ltd Stock Exchange , Press Release , Omparator Wve Sg9999014716 ,

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, April 13, 2023(NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has ....

New York , United States , Allan Malievsky , Stephen Bardin , Hercules Capital Inc , Life Sciences , Exchange Commission , Perception Neuroscience Inc , Securities Exchange , Perception Neuroscience , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Hercules Capital , Financial Condition , External Affairs ,